keyword
MENU ▼
Read by QxMD icon Read
search

Mirabegron

keyword
https://www.readbyqxmd.com/read/28322904/adding-mirabegron-to-solifenacin-to-treat-overactive-bladder-has-little-impact-on-post-void-residual-volume-or-urinary-retention-risk
#1
M J Drake, S MacDiarmid, S Al-Shukri, J Barkin, A Fianu-Jonasson, S Herschorn, M Huang, M Stoelzel, E Siddiqui
No abstract text is available yet for this article.
March 16, 2017: Urology
https://www.readbyqxmd.com/read/28293939/current-evidence-and-emerging-drug-therapies-for-overactive-bladder
#2
Matthew Izett, Martino Zacche, Ganesh Thiagamoorthy, Dudley Robinson, Linda Cardozo
Overactive bladder is a common symptom complex with health related quality of life impacts on the individual as well as utilising health resources. Antimuscarinic therapy has been the mainstay of treatment and is well supported within the literature and guidelines. However, compliance is poor due to lack of efficacy and adverse events leading to the development of novel therapies. Mirabegron, the B3-adrenoreceptor agonist has emerged as an evidence-based alternative first or second line therapy. Two decades after its first clinical application for overactive bladder, intravesical botulinum toxin is now an important part of any clinician's armamentarium for refractory cases...
March 14, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28286993/clinical-and-economic-impact-of-mirabegron-compared-with-antimuscarinics-for-the-treatment-of-overactive-bladder-in-canada
#3
Zalmai Hakimi, Jameel Nazir, Charles McCrea, Malin Berling, Francis Fatoye, Barbara Ramos, Adrian Wagg
BACKGROUND: The β3-adrenoceptor agonist, mirabegron, and antimuscarinic agents provide similar efficacy for the treatment of overactive bladder (OAB), but mirabegron appears to be associated with better persistence, perhaps due to an absence of anticholinergic side-effects. This study estimated the expected costs associated with the management of OAB in Canada from a societal perspective by utilizing real-world evidence. METHODS: An economic model with monthly cycles and a 1-year time horizon was developed to depict a treatment pathway for a hypothetical cohort of 100 patients with OAB...
March 12, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28273884/2d-qsar-and-3d-qsar-comsia-studies-on-a-series-of-r-2-2-1h-indol-2-yl-ethyl-amino-1-phenylethan-1-ol-with-human-%C3%AE-%C3%A2-adrenergic-activity
#4
Gastón Apablaza, Luisa Montoya, Cesar Morales-Verdejo, Marco Mellado, Mauricio Cuellar, Carlos F Lagos, Jorge Soto-Delgado, Hery Chung, Carlos David Pessoa-Mahana, Jaime Mella
The β₃ adrenergic receptor is raising as an important drug target for the treatment of pathologies such as diabetes, obesity, depression, and cardiac diseases among others. Several attempts to obtain selective and high affinity ligands have been made. Currently, Mirabegron is the only available drug on the market that targets this receptor approved for the treatment of overactive bladder. However, the FDA (Food and Drug Administration) in USA and the MHRA (Medicines and Healthcare products Regulatory Agency) in UK have made reports of potentially life-threatening side effects associated with the administration of Mirabegron, casting doubts on the continuity of this compound...
March 5, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28255232/profile-of-mirabegron-in-the-treatment-of-overactive-bladder-place-in-therapy
#5
REVIEW
Ala'a Sharaf, Hashim Hashim
Mirabegron is a relatively new drug introduced to treat overactive bladder syndrome. It can be used either on its own or as part of a combination. This drug has been extensively studied, with a good number of Phase II and Phase III trials showing promising outcomes. These studies show that mirabegron is an effective, well-tolerated drug, which could have some adverse effects of concern. In this review, we look at the trials on mirabegron, as well as its pharmacokinetics, mechanism of action, and side effects as documented in the literature...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28252310/-degree-of-satisfaction-of-patients-continuing-overactive-bladder-treatment-with-mirabegron
#6
K Švabík, J Mašata, J Krhut, R Zachoval, T Hanuš, M Halaška, L Horčička, L Krofta, M Hanáková, A Martan
OBJECTIVE: Overactive bladder syndrome is chronic disease with high prevalence rate (9-42%). This syndrome requires long term therapy, but the treatment persistence is after 3 months over all 26% with further decline in one-year period as low as 18.5%. Main reasons for stopping the treatment are low efficacy, the medication didnt work as expected and side effects. How much satisfied are patients with mirabegron persisting on its treatment? To answer this question, we provided secondary analysis of multicentre follow-up study of patients on mirabegron...
2017: Ceská Gynekologie
https://www.readbyqxmd.com/read/28228331/-efficacy-and-safety-of-available-therapies-in-the-management-of-idiopathic-overactive-bladder-a-systematic-review-of-the-literature
#7
J Moyson, F Legrand, M Vanden Bossche, T Quackels, T Roumeguère
OBJECTIVE: Study the efficacy and adverse events of different pharmacological lines in the treatment of idiopathic overactive bladder (iOAB). METHODS: PubMed research on meta-analyses and randomized controlled trials (RCT) focused on the efficacy and adverse effects of anticholinergics, botulinum toxin and mirabegron since 2005. RESULTS: Ten meta-analyses of anticholinergics were selected; 16 randomized controlled trials (ERC) comparing botulinum toxin A to either anticholinergic or placebo and 10 ERC studying mirabegron...
February 19, 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/28220521/indirect-treatment-comparison-itc-of-medical-therapies-for-an-overactive-bladder
#8
Aneta Obloza, Joshua Kirby, Derrick Yates, Philip Toozs-Hobson
BACKGROUND: Overactive bladder syndrome (OAB) is a chronic and prevalent condition which has a negative impact on Quality of Life. The National Institute of Clinical Excellence issued two documents which give slightly varying algorithms of pharmacotherapy for OAB, offering mirabegron as a possible treatment in certain circumstances. In the absence of trials involving a direct comparison of therapies, an indirect comparison can provide useful information on the difference in treatment effects between competing interventions...
February 21, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28208559/re-mirabegron-causes-relaxation-of-human-and-rat-corpus-cavernosum-could-it-be-a-potential-therapy-for-erectile-dysfunction
#9
Allen D Seftel
No abstract text is available yet for this article.
March 2017: Journal of Urology
https://www.readbyqxmd.com/read/28208543/re-efficacy-and-safety-of-mirabegron-add-on-therapy-to-solifenacin-in-incontinent-overactive-bladder-patients-with-an-inadequate-response-to-initial-4-week-solifenacin-monotherapy-a-randomised-double-blind-multicentre-phase-3b-study-beside
#10
https://www.readbyqxmd.com/read/28208541/re-mirabegron-relaxes-urethral-smooth-muscle-by-a-dual-mechanism-involving-%C3%AE-3-adrenoceptor-activation-and-%C3%AE-1-adrenoceptor-blockade
#11
Alan J Wein
No abstract text is available yet for this article.
March 2017: Journal of Urology
https://www.readbyqxmd.com/read/28196724/persistence-and-adherence-with-mirabegron-versus-antimuscarinic-agents-in-patients-with-overactive-bladder-a-retrospective-observational-study-in-uk-clinical-practice
#12
Christopher R Chapple, Jameel Nazir, Zalmai Hakimi, Sally Bowditch, Francis Fatoye, Florent Guelfucci, Amine Khemiri, Emad Siddiqui, Adrian Wagg
BACKGROUND: Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but may be different for mirabegron, a β3-adrenoceptor agonist with a different adverse event profile. OBJECTIVE: To compare persistence and adherence with mirabegron versus tolterodine extended release (ER) and other antimuscarinics in routine clinical practice over a 12-mo period. DESIGN, SETTING, AND PARTICIPANTS: Retrospective, longitudinal, observational study of anonymised data from the UK Clinical Practice Research Datalink GOLD database...
February 11, 2017: European Urology
https://www.readbyqxmd.com/read/28120446/phase-iii-study-to-assess-long-term-52-week-safety-and-efficacy-of-mirabegron-a-%C3%AE-3-adrenoceptor-agonist-in-japanese-patients-with-overactive-bladder
#13
Osamu Yamaguchi, Yasushi Ikeda, Sumito Ohkawa
OBJECTIVES: To investigate safety, tolerability and efficacy of long-term (52 weeks) open-label treatment with mirabegron 50 mg, with an optional dose increase to 100 mg, in patients with overactive bladder (OAB). METHODS: Patients received mirabegron 50 mg once daily for 52 weeks. If efficacy was insufficient at week 8, the dose could be increased to 100 mg. Safety was evaluated based on vital signs, adverse events (AEs), laboratory findings, electrocardiogram and post-void residual volume...
January 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28117002/b3-adrenoceptor-control-of-lower-gen%C3%A4-tour%C3%A4-nary-tract-organs-and-funct%C3%A4-on-in-male-an-overv%C3%A4-ew
#14
Ecem Kaya, Suresh C Sikka, Didem Yilmaz Oral, Isil Ozakca, Serap Gur
BACKGROUND: The sympathetic nervous system is one component of the nervous regulatory system of the physiological function of the lower genitourinary tract. Our knowledge on the role of this sympathetic system has advanced during the last decade due to the characterization of b3-adrenoceptors (b3-ARs) in the urogenital system. OBJECTIVE: This review focuses on the pharmacological and molecular evidence supporting the functional roles of β3-AR in male genitourinary tissues of various species...
January 20, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28073038/persistence-in-the-treatment-of-overactive-bladder-syndrome-oab-with-mirabegron-in-a-multicenter-clinical-study
#15
Alois Martan, Jaromir Masata, Jan Krhut, Roman Zachoval, Tomas Hanus, Kamil Svabik
OBJECTIVE: The objective of this project was to evaluate treatment persistence in patients being treated for overactive bladder syndrome (OAB) with mirabegron, employing clinical follow-up in a prospective, multicenter study. STUDY DESIGN: This is an analysis of patients who started treatment with mirabegron between May and September 2014 and were evaluated 1year after treatment commenced. During this evaluation we determined how many patients stopped treatment and established their reasons for discontinuation...
December 23, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28042309/the-link-between-vascular-dysfunction-bladder-ischemia-and-aging-bladder-dysfunction
#16
REVIEW
Karl-Erik Andersson, Donna B Boedtkjer, Axel Forman
The vascular supply to the human bladder is derived mainly from the superior and inferior vesical arteries, the latter being directly connected to the internal iliac artery. Aging is associated with an impairment of blood vessel function and changes may occur in the vasculature at the molecular, cellular and functional level. Pelvic arterial insufficiency may play an important role in the development of bladder dysfunctions such as detrusor overactivity (DO) and the overactive bladder syndrome. Chronic ischemia-related bladder dysfunction may progress to bladder underactivity and it would be desirable to treat not only lower urinary tract symptoms (LUTS) induced by chronic ischemia, but also the progression of the morphological bladder changes...
January 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28035527/new-and-emerging-therapies-and-targets-beta-3-agonists
#17
Lauriane Y M Michel, Jean-Luc Balligand
While crucial for the acute physiologic response to stress, the adrenergic system may become maladaptive upon prolonged stimulation in the course of development of heart failure. This has been the basis for the development of beta-blocking therapies, targeting mainly beta1-2 adrenoreceptors (B1-2AR). The third isotype, B3AR, was more recently identified in cardiac myocytes and endothelial cells from human (and many other animal species), where its distinctive coupling to nitric oxide and antioxidant pathways suggested potential protective properties that were unexploited so far...
December 30, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/28025920/impact-of-overactive-bladder-step-therapy-policies-on-medication-utilization-and-expenditures-among-treated-medicare-members
#18
Ibrahim M Abbass, Eleanor O Caplan, Daniel B Ng, Rita Kristy, Carol R Schermer, Pamela Bradt, Jenna M Collins, Wai Man Maria Chan, Brandon T Suehs
BACKGROUND: The impact of formulary management strategies on utilization and expenditures in overactive bladder (OAB) treatment has not been extensively investigated. In 2013, step therapy (ST) policies for 2 branded OAB treatments, mirabegron and fesoterodine, were removed from Humana Medicare Advantage Prescription Drug (MAPD) plans and Medicare prescription drug plans (PDP), allowing for an examination of the effect of ST policies on OAB medication use patterns and costs. OBJECTIVE: To assess the impact of removal of formulary restriction policies for mirabegron and fesoterodine on medication utilization patterns and costs associated with OAB treatment in Medicare patients...
January 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28009939/comparative-efficacy-and-tolerability-of-antimuscarinic-agents-and-the-selective-%C3%AE-3-adrenoceptor-agonist-mirabegron-for-the-treatment-of-overactive-bladder-which-is-more-preferable-as-an-initial-treatment
#19
Minoru Kobayashi, Akinori Nukui, Takao Kamai
OBJECTIVES: The objective of the present study was to evaluate comparative efficacy and tolerability of antimuscarinics and mirabegron as primary and salvage therapy in patients with overactive bladder (OAB). METHODS: Patients ≥50 years with OAB symptoms were enrolled. Patients were initially treated with antimuscrinics or mirabegron for 8 weeks. When patients were refractory or intolerant to an initial treatment, drugs were switched to the other. The initial and second-line efficacy was assessed at baseline, 4 and 8 weeks after the treatment having the following parameters of the International Prostatic Symptom Score (IPSS), quality of life (QOL) index, Overactive Bladder Symptom Score (OABSS) and post-void residual (PVR) urine volume...
December 23, 2016: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28001447/mirabegron-for-the-treatment-of-overactive-bladder-a-review-of-efficacy-safety-and-tolerability-with-a-focus-on-male-elderly-and-antimuscarinic-poor-responder-populations-and-patients-with-oab-in-asia
#20
REVIEW
Christopher R Chapple, Emad Siddiqui
Mirabegron is established as an alternative monotherapy to antimuscarinics for the treatment of overactive bladder (OAB) symptoms. Initial studies focused on Western populations, but over the past few years other populations and subpopulations have been evaluated. Areas covered: The authors' knowledge of the literature was used to develop the manuscript alongside a PubMed search ('mirabegron and clinical trial' and 'overactive bladder') to select independent studies of mirabegron. Up-to-date information is provided about the most recent mirabegron clinical trial and real-world efficacy, safety and tolerability data in a variety of patient populations with OAB, including those from different geographic areas, men, the elderly, and those with poor tolerability to antimuscarinics...
February 2017: Expert Review of Clinical Pharmacology
keyword
keyword
7718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"